The content on this site is intended for healthcare professionals only
Dr Josep Ribera talks to ecancer about his talk at ALL Assembly 2021.
He begins by saying that 20-30% of ALL transplant patients will relapse, making relapse one of the main issues, currently. Transplantation for patients with MRD- status has a lower chance of relapse, however, others will have to take additional measures. These measures can be divided between 2 sub-groups of patients with Ph+ ALL and Ph- ALL.
Dr Ribera then goes on to explain that for patients with Ph+ ALL a tyrosine kinase inhibitor (TKI) can be used for prophylaxis or preemptive use. For patients with Ph- ALL prophylactic donor lymphocyte infusion (DLI) can be used or immunotherapy with monoclonal antibodies, such as blinatumomab or inotuzumab.
He concludes by reiterating the main message of his talk, which is to prevent relapses rather than treating them, after transplantation in patients with ALL.
The Vanessa Moss Prize: celebrating research into cancer health disparities
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Multiple myeloma In Rwanda: The need for further research
OncoAlert Round Up for September 15-21, 2023
OncoAlert Round Up for August 25th - 31st, 2023
The use of IORT at Universitätsmedizin Mannheim hospital
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
African oncologists interaction with pharmaceutical industry
